缺血性二尖瓣反流的治疗选择:一项荟萃分析
该荟萃分析纳入12篇文献,比较缺血性二尖瓣反流(IMR)的当前治疗选择。主要终点为全因长期死亡率。结果显示MitraClip未优于单纯药物治疗;二尖瓣置换较瓣环成形术增加住院死亡率但降低再手术和再入院率;附加瓣下修复减少不良复合终点。
要点
- MitraClip与单纯药物治疗相比未显著改善死亡率和再入院。
- 中重度IMR中,二尖瓣置换较瓣环成形术住院死亡率更高但再手术和再入院更低。
- 瓣环成形联合瓣下修复较单纯瓣环成形减少术后主要不良事件风险。
核心结论
- MitraClip与药物治疗相比未改善结局。
- 中重度IMR中二尖瓣置换增加早期死亡率但降低再手术率和再入院率。
- 附加瓣下修复降低术后主要不良事件风险。
研究设计与样本
- 荟萃分析,共纳入12篇符合纳入标准的文献。
- 主要终点为全因长期死亡率。
- 次要终点包括围术期死亡率、非计划再入院、再手术及原文定义的复合终点。
主要发现
- MitraClip与单纯药物治疗相比在死亡率和重复住院方面无显著获益。
- 中度IMR患者中,在冠状动脉旁路移植术基础上附加二尖瓣手术未伴随临床改善。
- 二尖瓣置换较修复住院死亡率更高(OR 1.91;P = .009),但再手术率更低(OR 0.60;P = .05)、再入院率更低(OR 0.45;P < .02)。
- 限制性瓣环成形术联合瓣下修复较单纯瓣环成形术再入院更少(OR 0.50;P = .06)且不良复合终点更少(P = .009)。
临床怎么用
- 中重度IMR选择二尖瓣置换需权衡早期死亡率增加与再手术和再入院减少。
- 考虑在瓣环成形基础上附加瓣下修复以降低术后主要不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of ischemic mitral regurgitation (IMR) is in evolution, as percutaneous procedures and complex surgical repair have been recently investigated in randomized clinical trials and matched studies. This study aims to review and compare the current treatment options for IMR. METHODS: A comprehensive literature search was conducted using electronic databases. The primary outcome was all-cause long-term mortality. The secondary outcomes were perioperative mortality, unplanned rehospitalization, reoperation, and composite end points as defined in the original articles. RESULTS: A total of 12 articles met the inclusion criteria and were included in the final meta-analysis. The MitraClip procedure did not confer a significant benefit in mortality and repeated hospitalization compared with medical therapy alone. In patients with moderate IMR, the adjunct of mitral procedure over coronary artery bypass graft is not associated with clinical improvements. When evaluating mitral valve (MV) replacement versus repair, hospital mortality was greater among patients undergoing replacement (odds ratio [OR], 1.91; P = .009), but both reoperation and readmission rates were lower (OR, 0.60, P = .05; and OR, 0.45, P < .02, respectively). Comparing restrictive annuloplasty alone with adjunctive subvalvular repair, subvalvular procedures resulted in fewer readmissions (OR, 0.50; P = .06) and adverse composite end points (P = .009). CONCLUSIONS: MitraClip procedure is not associated with improved outcomes compared with medical therapy. MV replacement is associated with increased early mortality but reduced reoperation rate and readmission rate compared with MV repair using annuloplasty in moderate-to-severe IMR. Despite no significant benefit in isolated outcomes comparing annular and adjunct subvalvular procedures, the adjunct of subvalvular procedures reduces the risk of major postoperative adverse events.
引用
- Nappi F, Antoniou GA, Nenna A, et al. Treatment options for ischemic mitral regurgitation: A meta-analysis. J Thorac Cardiovasc Surg. 2020. PMID: 32713629. doi:10.1016/j.jtcvs.2020.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。